Obesity is a complex and heterogeneous chronic disease, affecting more than two-fifths of US adults.1,2,3,4,5 The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity treatment offers opportunities to mitigate the substantial health and economic burdens of obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.